Skip to main content

Table 1 Experimental groups and drug administration

From: Orexin antagonism and substance-P: Effects and interactions on polycystic ovary syndrome in the wistar rats

Groups

Received solutions

1

Control (only received vehicle)

2

PCOS (EV, 4.0 mg/kg); IM

3

PCOS + OX1Ra (1.0 mg/kg); IP

4

PCOS + OX2Ra (1.0 mg/kg); IP

5

PCOS + OX1Ra (1.0 mg/kg) + OX2Ra (1.0 mg/kg); IP

6

PCOS + NK1Ra (1.0 mg/kg); IP

7

PCOS + OX1Ra (1.0 mg/kg) + NK1Ra (1.0 mg/kg); IP

8

PCOS + OX2Ra (1.0 mg/kg) + NK1Ra (1.0 mg/kg); IP

9

PCOS + OX1Ra (1.0 mg/kg) + OX2Ra (1.0 mg/kg) + NK1Ra (1.0 mg/kg); IP

  1. PCOS: polycystic ovary syndrome, IM: intramuscular injection, IP: intraperitoneal injection, OX1Ra: orexin-1 receptor antagonist, OX2Ra: orexin-2 receptor antagonist, NK1Ra: neurokinin-1 receptor antagonist.